Search clinical trials for: Dapagliflozin Placebo

Total 54451 results

EMS

Recruiting

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Dyslipidemia Associated With Type II Diabetes Mellitus

Brazil
Ain Shams University

Completed

Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

Myocardial Infarction | Diabetes Mellitus, Type 2 | Myocardial Remodeling, Ventricular

Egypt
Ain Shams University

Completed

Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

Nephrotic Syndrome | Sodium-Glucose Transporter 2 Inhibitors

Egypt
Sabyasachi Sen

Terminated

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.

Type2 Diabetes
Cairo University

Active, not recruiting

Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis

Egypt
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
Nidae Alaa

Recruiting

Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

Diabetic Retinopathy

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
The University of Texas Health Science Center at...
AstraZeneca

Completed

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction (HFrEF)

United States, Canada, Denmark, Korea, Republic of, Brazil, Slovakia, Japan, South Africa, Sweden
Baylor College of Medicine

Terminated

Effect of Dapagliflozin on Inflammation and Endothelial Function

Type 2 Diabetes Mellitus

United States
Hellenic Society for Medical Education

Terminated

Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.

Diabetes Mellitus

Greece
University of Dundee
AstraZeneca; NHS Tayside

Completed

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? (DAPA-LVH)

Type 2 Diabetes | Left Ventricular Hypertrophy

United Kingdom
Christopher Bell
AstraZeneca

Completed

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Physical Activity

United States
Chong Kun Dang Pharmaceutical

Unknown

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Diabetes Mellitus, Type II

Korea, Republic of
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Healthy

Germany
4th Military Clinical Hospital with Polyclinic,...

Recruiting

CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL (PROTECTAA)

Heart Failure | Breast Cancer

Poland
AstraZeneca

Completed

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD)

Chronic Kidney Disease

United States, Italy, Spain, Brazil, Malaysia, Australia, South Africa, Hungary, Georgia, Japan, Bulgaria, Poland, Ukraine, Denmark, Argentina, Slovakia, Canada, Croatia, Netherlands
Insel Gruppe AG, University Hospital Bern

Completed

Dapagliflozin in Physical Exercise in Type 1 Diabetes

Diabetes Mellitus, Type 1

Switzerland
University Hospital Inselspital, Berne

Completed

Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes

Diabetes Mellitus, Type 1

Switzerland
AstraZeneca
Bristol-Myers Squibb

Completed

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada
AstraZeneca
Bristol-Myers Squibb

Completed

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Diabetes Mellitus, Type 2

Australia, United States, Italy, Argentina, Canada, Mexico, India, Peru, Spain, Denmark, France, Singapore, Puerto Rico
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
Tan Tock Seng Hospital

Recruiting

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes (DMVascular)

Diabetes

Singapore
University of Guadalajara

Recruiting

Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Obesity

Mexico
Cairo University
Aswan Heart Centre

Completed

Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)

Acute Heart Failure

Egypt
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital... and other collaborators

Recruiting

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM) (DEFORM)

Functional Mitral Regurgitation

China
Centro Medico Nacional Siglo XXI IMSS

Unknown

Effectiveness of Dapagliflozin for Weight Loss

Diabetes Mellitus, Type 2 | PreDiabetes | Obesity, Morbid

Mexico
Tulane University School of Medicine
AstraZeneca

Completed

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Hypertension | Type 2 Diabetes

United States
AstraZeneca
Antaros Medical; Bioventure Hub; 43183 Mölndal; Sweden

Completed

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus (DERISC)

Type 2 Diabetes Mellitus

Finland
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Hospices Civils de Lyon

Recruiting

Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients (DAPA-GUT)

Chronic Kidney Diseases

France
University of Campinas, Brazil
AstraZeneca

Completed

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (ADDENDA)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery Diseases

Brazil
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

Type 2 Diabetes

Sweden, France, Italy, Mexico, South Africa, Spain, Germany, Netherlands, Argentina, United Kingdom
Xiangtan Central Hospital
ZhuZhou Central Hospital; Second Xiangya Hospital of Central South University

Recruiting

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS) (ADIDAS)

Heart Failure | Anemia

China
University of Miami
AstraZeneca

Completed

Dapagliflozin Effects on Epicardial Fat

Type 2 Diabetes

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Type II Diabetes Mellitus

United States
Radboud University Medical Center

Completed

Effect of Dapagliflozin on IAH in T1DM

Hypoglycemia | Diabetes Mellitus, Type 1 | Hypoglycemia Unawareness

Netherlands
M.H.H. Kramer
AstraZeneca

Completed

Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED)

Diabetes Mellitus, Type 2 | Diabetic Nephropathies

Netherlands
LG Chem

Unknown

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
AstraZeneca
Uppsala University

Completed

Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. (DAPA-MI)

Heart Failure | Acute Myocardial Infarction

Sweden, United Kingdom
AstraZeneca

Completed

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER)

Heart Failure With Preserved Ejection Fraction

United States, Canada, Belgium, Czechia, Hungary, Taiwan, Vietnam, Mexico, Peru, China, Japan, Bulgaria, Spain, Brazil, Saudi Arabia, Netherlands, Romania, Russian Federation, Poland, Argentina
AstraZeneca

Completed

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF)

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

United States, Canada, Denmark, United Kingdom, Czechia, Vietnam, Germany, Brazil, India, China, Japan, Taiwan, Netherlands, Bulgaria, Slovakia, Hungary, Poland, Russian Federation, Argentina, Sweden

Search clinical trials for: Dapagliflozin Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations